SIENQ vs. BBLG, NAOV, NMTR, TCBP, SDCCQ, VRAX, CMRA, EVLO, SBFM, and SPRC
Should you be buying Sientra stock or one of its competitors? The main competitors of Sientra include Bone Biologics (BBLG), NanoVibronix (NAOV), 9 Meters Biopharma (NMTR), TC Biopharm (TCBP), SmileDirectClub (SDCCQ), Virax Biolabs Group (VRAX), Comera Life Sciences (CMRA), Evelo Biosciences (EVLO), Sunshine Biopharma (SBFM), and SciSparc (SPRC). These companies are all part of the "medical" sector.
Bone Biologics (NASDAQ:BBLG) and Sientra (NASDAQ:SIENQ) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, community ranking, risk and analyst recommendations.
Bone Biologics has a net margin of 0.00% compared to Bone Biologics' net margin of -65.93%. Bone Biologics' return on equity of 0.00% beat Sientra's return on equity.
34.3% of Bone Biologics shares are held by institutional investors. Comparatively, 17.1% of Sientra shares are held by institutional investors. 13.0% of Bone Biologics shares are held by company insiders. Comparatively, 1.5% of Sientra shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Bone Biologics has higher earnings, but lower revenue than Sientra. Bone Biologics is trading at a lower price-to-earnings ratio than Sientra, indicating that it is currently the more affordable of the two stocks.
Bone Biologics and Sientra both received 0 outperform votes by MarketBeat users.
In the previous week, Sientra's average media sentiment score of 0.59 beat Bone Biologics' score of 0.00 indicating that Bone Biologics is being referred to more favorably in the media.
Bone Biologics has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500. Comparatively, Sientra has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500.
Summary
Sientra beats Bone Biologics on 6 of the 11 factors compared between the two stocks.
Get Sientra News Delivered to You Automatically
Sign up to receive the latest news and ratings for SIENQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SIENQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SIENQ vs. The Competition
Related Companies and Tools
